Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Otinova Ear Spray
- Development stage
- Unknown
- Lead developer
- Circius Pharma
- Administration
- Otic
01
Overview
Otinova Ear Spray is a CE-marked, Class I self-care medical device developed and legally manufactured by Circius Pharma for topical otic treatment of external otitis. The spray is a Burow's-solution-based acidic preparation containing aluminium acetate, aluminium acetotartrate, acetic acid, and water. It acts locally as an astringent and drying agent, relieves itching, and creates an environment with antibacterial and antifungal effects; it contains no antibiotic or corticosteroid. ([otinova.com](https://otinova.com/wp-content/uploads/sites/4/2020/09/Otinova_produktblad_EN_lowres.pdf))
- Brand names
- Otinova
- Other names
- Otinova Ear Spray
Beyond the preview
Go deeper on Otinova Ear Spray.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Otinova Ear Spray.